[go: up one dir, main page]

Hara et al., 1995 - Google Patents

DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats

Hara et al., 1995

Document ID
238877515499081576
Author
Hara T
Yokoyama A
Tanabe K
Ishihara H
Iwamoto M
Publication year
Publication venue
Thrombosis and haemostasis

External Links

Snippet

We evaluated the antithrombotic effects of DX-9065a, a specific factor Xa inhibitor, using tissue thromboplastin-induced DIC (TP-DIC) and the arterio-venous shunt (AV shunt) in rats. Intravenous TP injection reduced the platelet counts and fibrinogen concentrations in blood …
Continue reading at www.thieme-connect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII

Similar Documents

Publication Publication Date Title
Hara et al. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats
Andersson et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma
Taniuchi et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa
van't Veer et al. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II
Griffin et al. Deficiency of protein C in congenital thrombotic disease.
Ofosu et al. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin
Marlar et al. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation
Bertina Hereditary protein S deficiency
Minnema et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor.
Wesselschmidt et al. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin
Samama et al. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs)
Fuchs et al. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.
Pieters et al. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma
Agnelli et al. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin
Jochum et al. Clotting and other plasma factors in experimental endotoxemia: Inhibition of degradation by exogenous proteinase inhibitors
Ofosu et al. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma
Tollefsen et al. Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.
Rosen Bleeding problems in the cancer patient
Mirshahi et al. Glycosylation of human fibrinogen and fibrin in vitro its consequences on the properties of fibrin (ogen)
Lormeau et al. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide
EP0535129B1 (en) An anticoagulant preparation
Marci et al. A review of the clinical indications for the plasma heparin assay
Bendetowicz et al. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin (enoxaparin)
Gerotziafas et al. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma
Gallistl et al. Thrombin-hirudin complex formation, thrombin-antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma